Agueda Santana

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research

D. Gomez, D. Alonso, Y. Perera, 2011, Molecular and Cellular Biochemistry.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

D. Alonso, O. Mendoza, Y. Perera, 2008, Molecular and Cellular Biochemistry.

Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

D. Alonso, P. López-Saura, S. Perea, 2009, BMC Cancer.